Clinical trial
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease…
NCT00189488 · Swedish Orphan Biovitrum, Industry · Completed
Key facts
| NCT number | NCT00189488 |
|---|---|
| Title | Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation |
| Official title | A Randomized, Double-blind, Placebo-controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation |
| Lead sponsor | Swedish Orphan Biovitrum, Industry |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Graft Versus Host Disease, Hematologic Malignancies |
| Intervention type | Drug, Other, Procedure |
| Interventions | Palifermin, Placebo, Conditioning Regimen, Allogeneic stem cell transplant, Methotrexate |
| Enrollment | 155 |
| Start date | Dec 1, 2005 |
| Primary completion | Nov 1, 2008 |
| Completion | Aug 1, 2013 |
| First posted | Sep 19, 2005 |
| Last update posted | Sep 15, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: